Results 31 to 40 of about 704 (128)

Issues in design and interpretation of MDR-TB clinical trials: report of the first Global MDR-TB Clinical Trials Landscape Meeting [PDF]

, 2015
Recognizing that the current MDR-TB regimen is suboptimal and based on low-quality evidence, the Global MDR-TB Clinical Trials Landscape Meeting was held in December, 2014 to strategize about coordination of research and development of new treatment ...
Bain, Lisa J, Horsburgh, C Robert, Mitnick, Carole D, Rusen, ID   +3 more
core   +5 more sources

Tuberculosis: Development of New Drugs and Treatment Regimens

Jurnal Respirasi, 2021
Tuberculosis (TB) still becomes a public health crisis. Drug-resistant TB (DR-TB) becomes a concern as the increasing DR-TB cases in countries with high TB burden.
Soedarsono Soedarsono
doaj   +1 more source

MmpL3 Inhibition as a Promising Approach to Develop Novel Therapies against Tuberculosis: A Spotlight on SQ109, Clinical Studies, and Patents Literature

Biomedicines, 2022
Tuberculosis (TB) is accountable for considerable global morbidity and mortality. Effective TB therapy with multiple drugs completes in about six months.
Mohd. Imran, Mandeep Kumar Arora, Anurag Chaudhary, Shah Alam Khan, Mehnaz Kamal, Manal Mutlaq Alshammari, Raghad Mohammad Alharbi, Nuha Abdullah Althomali, Ibrahim Mohammed Alzimam, Abdullah Ayed Alshammari, Bashair Hamed Alharbi, Amer Alshengeti, Abdulmonem A. Alsaleh, Shayea A. Alqahtani, Ali A. Rabaan   +14 more
doaj   +1 more source

Linezolid pharmacokinetics in MDR-TB : a systematic review, meta-analysis and Monte Carlo simulation [PDF]

, 2018
This work was supported by the Wellcome Trust (grant numbers 109129/Z/15/Z to JM and 105620/Z/14/Z to DS and MC).Objectives The oxazolidinone linezolid is an effective component of drug - resistant TB treatment, but use is limited by toxicity and the ...
Alffenaar, Jan-Willem C, Bolhuis, Mathieu, Bonnett, Laura, Caws, Maxine, Dartois, Véronique, Davies, Geraint, Johnson, John L, Millard, James, Model, Eva Maria, Pertinez, Henry, Sloan, Derek James, Tiberi, Simon   +11 more
core   +5 more sources

Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients with programmatically incurable tuberculosis: a prospective cohort study. [PDF]

, 2017
BACKGROUND: The emergence of programmatically incurable tuberculosis threatens to destabilise control efforts. The aim of this study was to collect prospective patient-level data to inform treatment and containment strategies.
Abdallah, Abdallah M, Ben-Rached, Fathia, Clark, Taane G, Dheda, Keertan, Dolby, Tania, Esmail, Aliasgar, Fennelly, Kevin P, Gumbo, Tawanda, Lesosky, Maia, Limberis, Jason D, Mastrapa, Barbara, McNerney, Ruth, Pain, Arnab, Phelan, Jody, Pietersen, Elize, Simpson, John, Sirgel, Frederick A, Smith, Liezel, Streicher, Elizabeth M, Te Riele, Julian, Theron, Grant, van Helden, Paul, Warren, Robin M   +22 more
core   +1 more source

Challenges and recent progress in drug discovery for tropical diseases [PDF]

, 2018
Infectious tropical diseases have a huge effect in terms of mortality and morbidity, and impose a heavy economic burden on affected countries. These diseases predominantly affect the world’s poorest people.
A Guidi, A Hoerauf, AF Francisco, AK Kakkar, AK Njamnshi, AN Cowell, B Amadi, B Baragana, B Blasco, B Wahid, Beatriz Baragaña, CA Fux, CD Huston, CE Barry III, CE Coltart, D Sissoko, DA Lamprecht, DG Brown, DI Stanisic, DM Plouffe, DS Shepard, DT Hoagland, E Bushell, E Chatelain, E Chatelain, E Check Hayden, E Tacconelli, E Torreele, E Wit de, F Josephson, F Macintyre, FJ Sanchez-Valdez, FX Blanc, G Priotto, G-Finder, H Myllymaki, Hotez, I Angulo-Barturen, I Kramnik, I Molina, Ian H. Gilbert, ID Olaru, IPFMA, J Keiser, J Liu, J Whitehorn, JG Kublin, JN Burrows, JP Sarathy, JR Perfect, JS McCarthy, JS McCarthy, K Awadzi, K Basile, KH Mayer, KK Irwin, KL Kotloff, L Conteh, LJ Zhan, LL Silver, M Lee, M Matsumoto, MA Hulverson, Manu De Rycker, MB Jimenez-Diaz, MC Field, MC Pawlowic, MF Fromm, ML Ang, ML Hovlid, MS Love, MY Lim, N Ford, N Gyawali, N Lander, N Woodford, NA Meanwell, NJ White, NJ White, NJ White, NR Mansour, OP Singh, P Buscher, P Horvath, P Steinmann, PG Wyatt, PJ Hotez, R Rajasingham, R Taylor, RT Jacobs, S Baker, S Brooker, S Khare, S Sayasone, SA Mikolajczak, SD Pion, SH Xiao, SM Hammer, Suzanne L. Duce, T Paquet, TF Koning-Ward de, TK Warren, TN Wells, U Klarmann-Schulz, UH Manjunatha, UH Manjunatha, V Boldescu, V Mesu, VK Wong, W Checkley, W Moser, W Moser, W Zheng, Warren, World Health Organization, X Li, Y Debing, Y Wang   +117 more
core   +2 more sources

Treatment-shortening regimens for tuberculosis: updates and future priorities [PDF]

, 2023
In the past 2 years, remarkable advances have been made in shortening tuberculosis (TB) treatment. In particular, four clinical trials (Study 31/A5349, Nix-TB, ZeNix and TB-PRACTECAL) have provided evidence of the efficacy of regimens based on new and ...
Adepoju, VA, Duarte, R, Lange, C, Phillips, PPJ, Saluzzo, F   +4 more
core   +2 more sources

Antitubercular specific activity of ibuprofen and the other 2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay [PDF]

, 2013
Objectives: Lead antituberculosis (anti-TB) molecules with novel mechanisms of action are urgently required to fuel the anti-TB drug discovery pipeline.
Bhakta, Sanjib, Birchall, K., Evangelopoulos, Dimitrios, Gibbons, S., Gupta, Antima, Guzman, Juan D., Malkinson, J., McHugh, T.D., Mwaigwisya, S., Saxty, B.   +9 more
core   +1 more source

Assessment of treatment response in tuberculosis [PDF]

, 2016
Antibiotic treatment of tuberculosis has a duration of several months. There is significant variability of the host immune response and the pharmacokinetic-pharmacodynamic properties of Mycobacterium tuberculosis sub-populations at the site of disease. A
Du Bruyn, E, Morris, T, Rockwood, N, Wilkinson, RJ   +3 more
core   +1 more source

Application of metabolomics to drug discovery and understanding the mechanisms of action of medicinal plants with anti‐tuberculosis activity

Clinical and Translational Medicine, Volume 7, Issue 1, December 2018., 2018
AbstractHuman tuberculosis (TB) is amongst the oldest and deadliest human bacterial diseases that pose major health, social and economic burden at a global level. Current regimens for TB treatment are lengthy, expensive and ineffective to emerging drug resistant strains. Thus, there is an urgent need for identification and development of novel TB drugs
Naasson Tuyiringire, Deusdedit Tusubira, Jean‐Pierre Munyampundu, Casim Umba Tolo, Claude M. Muvunyi, Patrick Engeu Ogwang   +5 more
wiley   +1 more source